Selected research
Industry Research
Pharmaceutical & Biotechnology IP Services Industry Research Report 2026
Market perspective
The global Pharmaceutical & Biotechnology IP Services market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Pharmaceutical & Biotechnology IP Services market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Pharmaceutical & Biotechnology IP Services market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Pharmaceutical & Biotechnology IP Services market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Pharmaceutical & Biotechnology IP Services include Finnegan, MBHB, Wolf Greenfield & Sacks, P.C., Kirkland & Ellis LLP, Sterne Kessler, Nelson Mullins Riley & Scarborough LLP, Pabst Patent Group, Excelon IP and Pharma Patents International, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Pharmaceutical & Biotechnology IP Services market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Pharmaceutical & Biotechnology IP Services.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pharmaceutical & Biotechnology IP Services Market by Company
Finnegan
MBHB
Wolf Greenfield & Sacks, P.C.
Kirkland & Ellis LLP
Sterne Kessler
Nelson Mullins Riley & Scarborough LLP
Pabst Patent Group
Excelon IP
Pharma Patents International
J A Kemp
DLA Piper
Michael Best & Friedrich LLP
Troutman Pepper
Cooley LLP
Fish & Richardson
Pharmaceutical & Biotechnology IP Services Segment by Type
Patents
Copyrights
Trademarks
Others
Pharmaceutical & Biotechnology IP Services Segment by Application
Pharmaceutical Companies
Contract Research Organizations (CROs)
Others
Pharmaceutical & Biotechnology IP Services Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmaceutical & Biotechnology IP Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pharmaceutical & Biotechnology IP Services and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmaceutical & Biotechnology IP Services.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Pharmaceutical & Biotechnology IP Services companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Patents
- Copyrights
- Trademarks
- Others
Applications
- Pharmaceutical Companies
- Contract Research Organizations (CROs)
- Others
Companies covered
- Finnegan
- MBHB
- Wolf Greenfield & Sacks, P.C.
- Kirkland & Ellis LLP
- Sterne Kessler
- Nelson Mullins Riley & Scarborough LLP
- Pabst Patent Group
- Excelon IP
- Pharma Patents International
- J A Kemp
- DLA Piper
- Michael Best & Friedrich LLP
- Troutman Pepper
- Cooley LLP
- Fish & Richardson
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Pharmaceutical & Biotechnology IP Services by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Patents
- 2.2.3 Copyrights
- 2.2.4 Trademarks
- 2.2.5 Others
- 2.3 Pharmaceutical & Biotechnology IP Services by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmaceutical Companies
- 2.3.3 Contract Research Organizations (CROs)
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Pharmaceutical & Biotechnology IP Services Breakdown Data by Type
- 3.1 Global Pharmaceutical & Biotechnology IP Services Historic Market Size by Type (2021-2026)
- 3.2 Global Pharmaceutical & Biotechnology IP Services Forecasted Market Size by Type (2027-2032)
4 Pharmaceutical & Biotechnology IP Services Breakdown Data by Application
- 4.1 Global Pharmaceutical & Biotechnology IP Services Historic Market Size by Application (2021-2026)
- 4.2 Global Pharmaceutical & Biotechnology IP Services Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Pharmaceutical & Biotechnology IP Services Market Perspective (2021-2032)
- 5.2 Global Pharmaceutical & Biotechnology IP Services Growth Trends by Region
- 5.2.1 Global Pharmaceutical & Biotechnology IP Services Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Pharmaceutical & Biotechnology IP Services Historic Market Size by Region (2021-2026)
- 5.2.3 Pharmaceutical & Biotechnology IP Services Forecasted Market Size by Region (2027-2032)
- 5.3 Pharmaceutical & Biotechnology IP Services Market Dynamics
- 5.3.1 Pharmaceutical & Biotechnology IP Services Industry Trends
- 5.3.2 Pharmaceutical & Biotechnology IP Services Market Drivers
- 5.3.3 Pharmaceutical & Biotechnology IP Services Market Challenges
- 5.3.4 Pharmaceutical & Biotechnology IP Services Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Pharmaceutical & Biotechnology IP Services Players by Revenue
- 6.1.1 Global Top Pharmaceutical & Biotechnology IP Services Players by Revenue (2021-2026)
- 6.1.2 Global Pharmaceutical & Biotechnology IP Services Revenue Market Share by Players (2021-2026)
- 6.2 Global Pharmaceutical & Biotechnology IP Services Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Pharmaceutical & Biotechnology IP Services Head Office and Area Served
- 6.4 Global Pharmaceutical & Biotechnology IP Services Players, Product Type & Application
- 6.5 Global Pharmaceutical & Biotechnology IP Services Manufacturers Established Date
- 6.6 Global Pharmaceutical & Biotechnology IP Services Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Pharmaceutical & Biotechnology IP Services Market Size (2021-2032)
- 7.2 North America Pharmaceutical & Biotechnology IP Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Pharmaceutical & Biotechnology IP Services Market Size by Country (2021-2026)
- 7.4 North America Pharmaceutical & Biotechnology IP Services Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Pharmaceutical & Biotechnology IP Services Market Size (2021-2032)
- 8.2 Europe Pharmaceutical & Biotechnology IP Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Pharmaceutical & Biotechnology IP Services Market Size by Country (2021-2026)
- 8.4 Europe Pharmaceutical & Biotechnology IP Services Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Pharmaceutical & Biotechnology IP Services Market Size (2021-2032)
- 9.2 Asia-Pacific Pharmaceutical & Biotechnology IP Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Pharmaceutical & Biotechnology IP Services Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Pharmaceutical & Biotechnology IP Services Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Pharmaceutical & Biotechnology IP Services Market Size (2021-2032)
- 10.2 South America Pharmaceutical & Biotechnology IP Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Pharmaceutical & Biotechnology IP Services Market Size by Country (2021-2026)
- 10.4 South America Pharmaceutical & Biotechnology IP Services Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Pharmaceutical & Biotechnology IP Services Market Size (2021-2032)
- 11.2 Middle East & Africa Pharmaceutical & Biotechnology IP Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Pharmaceutical & Biotechnology IP Services Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Pharmaceutical & Biotechnology IP Services Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Finnegan
- 12.1.1 Finnegan Company Information
- 12.1.2 Finnegan Business Overview
- 12.1.3 Finnegan Revenue in Pharmaceutical & Biotechnology IP Services Business (2021-2026)
- 12.1.4 Finnegan Pharmaceutical & Biotechnology IP Services Product Portfolio
- 12.1.5 Finnegan Recent Developments
- 12.2 MBHB
- 12.2.1 MBHB Company Information
- 12.2.2 MBHB Business Overview
- 12.2.3 MBHB Revenue in Pharmaceutical & Biotechnology IP Services Business (2021-2026)
- 12.2.4 MBHB Pharmaceutical & Biotechnology IP Services Product Portfolio
- 12.2.5 MBHB Recent Developments
- 12.3 Wolf Greenfield & Sacks, P.C.
- 12.3.1 Wolf Greenfield & Sacks, P.C. Company Information
- 12.3.2 Wolf Greenfield & Sacks, P.C. Business Overview
- 12.3.3 Wolf Greenfield & Sacks, P.C. Revenue in Pharmaceutical & Biotechnology IP Services Business (2021-2026)
- 12.3.4 Wolf Greenfield & Sacks, P.C. Pharmaceutical & Biotechnology IP Services Product Portfolio
- 12.3.5 Wolf Greenfield & Sacks, P.C. Recent Developments
- 12.4 Kirkland & Ellis LLP
- 12.4.1 Kirkland & Ellis LLP Company Information
- 12.4.2 Kirkland & Ellis LLP Business Overview
- 12.4.3 Kirkland & Ellis LLP Revenue in Pharmaceutical & Biotechnology IP Services Business (2021-2026)
- 12.4.4 Kirkland & Ellis LLP Pharmaceutical & Biotechnology IP Services Product Portfolio
- 12.4.5 Kirkland & Ellis LLP Recent Developments
- 12.5 Sterne Kessler
- 12.5.1 Sterne Kessler Company Information
- 12.5.2 Sterne Kessler Business Overview
- 12.5.3 Sterne Kessler Revenue in Pharmaceutical & Biotechnology IP Services Business (2021-2026)
- 12.5.4 Sterne Kessler Pharmaceutical & Biotechnology IP Services Product Portfolio
- 12.5.5 Sterne Kessler Recent Developments
- 12.6 Nelson Mullins Riley & Scarborough LLP
- 12.6.1 Nelson Mullins Riley & Scarborough LLP Company Information
- 12.6.2 Nelson Mullins Riley & Scarborough LLP Business Overview
- 12.6.3 Nelson Mullins Riley & Scarborough LLP Revenue in Pharmaceutical & Biotechnology IP Services Business (2021-2026)
- 12.6.4 Nelson Mullins Riley & Scarborough LLP Pharmaceutical & Biotechnology IP Services Product Portfolio
- 12.6.5 Nelson Mullins Riley & Scarborough LLP Recent Developments
- 12.7 Pabst Patent Group
- 12.7.1 Pabst Patent Group Company Information
- 12.7.2 Pabst Patent Group Business Overview
- 12.7.3 Pabst Patent Group Revenue in Pharmaceutical & Biotechnology IP Services Business (2021-2026)
- 12.7.4 Pabst Patent Group Pharmaceutical & Biotechnology IP Services Product Portfolio
- 12.7.5 Pabst Patent Group Recent Developments
- 12.8 Excelon IP
- 12.8.1 Excelon IP Company Information
- 12.8.2 Excelon IP Business Overview
- 12.8.3 Excelon IP Revenue in Pharmaceutical & Biotechnology IP Services Business (2021-2026)
- 12.8.4 Excelon IP Pharmaceutical & Biotechnology IP Services Product Portfolio
- 12.8.5 Excelon IP Recent Developments
- 12.9 Pharma Patents International
- 12.9.1 Pharma Patents International Company Information
- 12.9.2 Pharma Patents International Business Overview
- 12.9.3 Pharma Patents International Revenue in Pharmaceutical & Biotechnology IP Services Business (2021-2026)
- 12.9.4 Pharma Patents International Pharmaceutical & Biotechnology IP Services Product Portfolio
- 12.9.5 Pharma Patents International Recent Developments
- 12.10 J A Kemp
- 12.10.1 J A Kemp Company Information
- 12.10.2 J A Kemp Business Overview
- 12.10.3 J A Kemp Revenue in Pharmaceutical & Biotechnology IP Services Business (2021-2026)
- 12.10.4 J A Kemp Pharmaceutical & Biotechnology IP Services Product Portfolio
- 12.10.5 J A Kemp Recent Developments
- 12.11 DLA Piper
- 12.11.1 DLA Piper Company Information
- 12.11.2 DLA Piper Business Overview
- 12.11.3 DLA Piper Revenue in Pharmaceutical & Biotechnology IP Services Business (2021-2026)
- 12.11.4 DLA Piper Pharmaceutical & Biotechnology IP Services Product Portfolio
- 12.11.5 DLA Piper Recent Developments
- 12.12 Michael Best & Friedrich LLP
- 12.12.1 Michael Best & Friedrich LLP Company Information
- 12.12.2 Michael Best & Friedrich LLP Business Overview
- 12.12.3 Michael Best & Friedrich LLP Revenue in Pharmaceutical & Biotechnology IP Services Business (2021-2026)
- 12.12.4 Michael Best & Friedrich LLP Pharmaceutical & Biotechnology IP Services Product Portfolio
- 12.12.5 Michael Best & Friedrich LLP Recent Developments
- 12.13 Troutman Pepper
- 12.13.1 Troutman Pepper Company Information
- 12.13.2 Troutman Pepper Business Overview
- 12.13.3 Troutman Pepper Revenue in Pharmaceutical & Biotechnology IP Services Business (2021-2026)
- 12.13.4 Troutman Pepper Pharmaceutical & Biotechnology IP Services Product Portfolio
- 12.13.5 Troutman Pepper Recent Developments
- 12.14 Cooley LLP
- 12.14.1 Cooley LLP Company Information
- 12.14.2 Cooley LLP Business Overview
- 12.14.3 Cooley LLP Revenue in Pharmaceutical & Biotechnology IP Services Business (2021-2026)
- 12.14.4 Cooley LLP Pharmaceutical & Biotechnology IP Services Product Portfolio
- 12.14.5 Cooley LLP Recent Developments
- 12.15 Fish & Richardson
- 12.15.1 Fish & Richardson Company Information
- 12.15.2 Fish & Richardson Business Overview
- 12.15.3 Fish & Richardson Revenue in Pharmaceutical & Biotechnology IP Services Business (2021-2026)
- 12.15.4 Fish & Richardson Pharmaceutical & Biotechnology IP Services Product Portfolio
- 12.15.5 Fish & Richardson Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst